Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation): 2-Day Workshop

Sign for Notice Everyday

Home Post Event 2025Event 2026Event By Topic By Country Contact

Our Sponsors

Process Validation Guidance Requirements (FDA and EU Annex 15: Qualifications and Validation): 2-Day Workshop

Website http://bit.ly/2aML1qO | Edit Freely

Category FDA GXP Compliance - Pharmaceuticals;

Deadline: August 17, 2016 | Date: August 18, 2016-August 19, 2016

Venue/Country: Burlingame, U.S.A

Updated: 2016-08-03 20:35:58 (GMT+9)

Call For Papers - CFP

The Process Validation Guidelines (January 2011) and the EU Annex 15: Qualification and Validation (October 2015) outline the general principles and approaches the two regulatory bodies consider appropriate elements of process validation for the manufacture of human and animal drugs and biological products, including Active Pharmaceutical Ingredients (APIs). These guidances align Process Validation activities with a product lifecycle concept and with existing FDA and EU guidances, including the FDA/International Conference on Harmonization (ICH), Guidance for Industry, Q8 (R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System. The lifecycle concept, new to these Guidances, link product and process development, qualification of the commercial manufacturing process, and maintenance of the process in a state of control during routine commercial production. These guidances also support process improvement and innovation through sound science and risk management. The new Process Validation Guideline/Practice incorporate elements of Process Validation as early as the Research and Development phase, and continues onward through Technology Transfer, into the Phase 1 IND Clinical Trial manufacturing phase, and ultimately into Phase 2 and 3, and then commercial manufacturing.

Learning Objectives:

Why these FDA Guidance/EU Guidelines for Industry - Process Validation is so important to the pharmaceutical and biotechnology industry.

What FDA segments are included and excluded within the "NEW" Process Validation.

Where does the Process Validation commence.

What are the Three Stages and Where DThey Apply within the NEW Process Validation.

How Stage 1 integrates with Phase 1.

The Validation approaches that are included within this Guidance document.

The Statutory and Regulatory Requirements for Process Validation.

Who Will Benefit:

Those who will benefit from this seminar include

Product Development

Project Management

Regulatory Compliance

Quality Assurance

Quality Control

Note:

Use coupon code NB5SQH8N and get 10% off on registration.

For Registration:

http://www.complianceonline.com/fda-eu-annex15-ich-process-validation-qualification-cgmp-ppq-seminar-training-80375SEM-prdsm?channel=ourglocal

Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.